Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti- Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti- Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SELECT-NEXT
  • Sponsors AbbVie; AbbVie Germany

    • Most Recent Events

    • 15 Nov 2023 Results of an integrated analysis assessing gene expression and methylation identifies biomarkers associated with mode of action of Upadacitinib from three phase 3 clinical studies: SELECT-BEYOND, SELECT-COMPARE and SELECT-NEXT presented at the ACR Convergence 2023
    • 12 Jun 2023 Results of post-hoc pooled analysis of 6 studies (NCT02706873, NCT02675426, NCT02629159, NCT02706951, NCT02706847 and NCT03086343) assessing potential risk of upadacitinib in a similar RA population, published in the Annals of the Rheumatic Diseases.
    • 01 May 2023 Results of integrated safety analysis from NCT02706873; , NCT02675426;, NCT02629159; NCT02706951;NCT02706847; NCT03086343, published in the Clinical Rheumatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top